Description
Anti-PMEL17 Antibody, Non-Fucosylated (BioBet-1533ZP) is a human monoclonal IgG antibody against PMEL17. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Melanoma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced PMEL17 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
PMEL
Full Name
premelanosome protein
Background
This gene encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Jan 2011]
Alternative Names
PMEL; premelanosome protein; P1; SI; SIL; ME20; P100; SILV; ME20M; gp100; ME20-M; PMEL17; D12S53E; melanocyte protein PMEL; melanocyte protein mel 17; silver, mouse, homolog of; melanocyte protein Pmel 17; melanosomal matrix protein17; silver locus protein homolog; melanoma-associated ME20 antigen; melanocytes lineage-specific antigen GP100;
Gene ID
6490
Cellular Localization
Golgi apparatus, Endosome, Endoplasmic reticulum
Involvement in Disease
Diseases associated with PMEL include Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 and Melanoma In Congenital Melanocytic Nevus.
Function
It plays a central role in the biogenesis of melanosomes. Participated in the maturation of melanosomes from stage I to stage II. The transition from stage I melanosomes to stage II melanosomes involves the elongation of vesicles and the appearance within a unique fiber structure. The release of its soluble form ME20-S can protect tumor cells from antibody-mediated immunity.
Field of research
Cancer antibody; Controls and Markers antibody; Metabolism antibody; Signaling Transduction antibody
Post-translational modifications
A small amount of P1/P100 (major form) undergoes glycosylation to yield P2/P120 (minor form). P2 is cleaved by a furin-like proprotein convertase (PC) in a pH-dependent manner in a post-Golgi, prelysosomal compartment into two disulfide-linked subunits: a large lumenal subunit, M-alpha/ME20-S, and an integral membrane subunit, M-beta. Despite cleavage, only a small fraction of M-alpha is secreted, whereas most M-alpha and M-beta remain associated with each other intracellularly. M-alpha is further processed to M-alpha N and M-alpha C. M-alpha C further undergoes processing to yield M-alpha C1 and M-alpha C3 (M-alpha C2 in the case of PMEL17-is or PMEL17-ls). Formation of intralumenal fibrils in the melanosomes requires the formation of M-alpha that becomes incorporated into the fibrils. Stage II melanosomes harbor only Golgi-modified Pmel17 fragments that are derived from M-alpha and that bear sialylated O-linked oligosaccharides. N-glycosylated. O-glycosylated; contains sialic acid.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1533ZP
Description
The products are isolated antibody that targets PMEL17, and these agents bind to PMEL17 are used for the diagnosis and treatment of PMEL17-associated conditions, such as cancer.
Antibody Indication
Melanoma
